Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Among those patients who were employed at baseline and those who maintained employment at weeks 12 and 24, there were reduced presenteeism (percentage of work-time impaired) and work productivity loss in baricitinib-treated groups but these did not reach statistical significance compared with placebo; similar results were observed for absenteeism at week 12, but were not maintained at week 24 (see online supplementary table S4 ).

also in 111,027 other papers